Prescription drug spending between 2014 and 2015 increased at a much higher rate among health exchange plans compared with commercial plans, Medicare, and Medicaid plans. Express Scripts highlighted 3 select trends that are having the biggest impact on plans.
Express Scripts’ most recent (June 2016) Exchange Pulse Report presents 2 years of the company’s data and trend tracking that reflect its experience as a pharmacy benefit manager for a third of the more than 9 million Americans enrolled in an insurnace exchange benefit in 2015.
The Exchange Pulse Report focuses on 3 select trends that are having the biggest impact on plans and tracks year-over-year increases and decreases in pharmacy utilization and cost. The 3 insights highlighted in the report are those that the company believes health plans need to understand to ensure they continue to offer an affordable and meaningful benefit and be ready for any new challenges presented by the changing healthcare environment.
Prescription drug spending between 2014 and 2015 increased at a much higher rate among health exchange plans compared with commercial plans, Medicare, and Medicaid plans. An important factor to consider is that many enrollees in the public exchange plans had never had a drug benefit before, and many enrollees are seeking treatment for pre-existing and newly diagnosed conditions and are still only beginning to fully understand and take advantage of their benefits. The 3 trends the report highlights are:
The report also made several recommendations for plans to prepare for the near future.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More